Konzilium s.r.o.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Epilepsy4 trials
• Alzheimer disease2 trials
• Migraine1 trial
• Mild cognitive impairment1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Completed7 trials

Lead sponsor

• Sk Life Science Inc.2 trials
• UCB Biopharma SRL2 trials
• H. Lundbeck A/S1 trial
• Inmune Bio, Inc.1 trial
• Otsuka Pharmaceutical Development & Commercialization Inc.1 trial

Closed trials

• Active, not recruiting

  A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  NCT06315322· Phase 3· UCB Biopharma SRL· Source

• Completed

  A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  NCT06323928· Phase 2· H. Lundbeck A/S· Source

• Completed

  A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

  NCT05318976· Phase 2· Inmune Bio, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

  NCT04666610· Phase 3· UCB Biopharma SRL· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

  NCT04464564· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Completed

  A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

  2023-506688-32-00· Phase 3· Sk Life Science Inc.· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures

  2023-506687-13-00· Phase 3· Sk Life Science Inc.· Source